ProCE Banner Activity

Expert Answers to Frequently Asked Questions on Immunotherapy for Patients With Bladder Cancer

Clinical Thought
In this commentary, experts provide their answers to frequently asked questions on the use of immunotherapy in the management of patients with bladder cancer.

Released: August 18, 2020

Expiration: August 17, 2021

No longer available for credit.

Share

Faculty

Matthew I. Milowsky

Matthew I. Milowsky, MD

Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Daniel P. Petrylak

Daniel P. Petrylak, MD

Professor of Medicine
Smilow Cancer Center
Yale University Medical Center
New Haven, Connecticut

Jonathan Rosenberg

Jonathan Rosenberg, MD

Attending Physician, Chief
Genitourinary Oncology Service
Division of Solid Tumor Oncology
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by National Comprehensive Cancer Network.
ProCE Banner

Supporters

Supported by an independent educational grant from Merck & Co., Inc.

Supported by educational grants from

Astellas Seattle Genetics

QED Therapeutics

Faculty Disclosure

Primary Author

Matthew I. Milowsky, MD

Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Matthew I. Milowsky, MD, has disclosed that he has received consulting fees from BioClin Therapeutics and funds for research support paid to his institution from Acerta, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Cerulean, Clovis, Constellation, Incyte, Innocrin, Inovio, Jounce, MedImmune, Merck, Roche/Genentech, Seattle Genetics, Syndax, and X4 Pharmaceuticals.

Daniel P. Petrylak, MD

Professor of Medicine
Smilow Cancer Center
Yale University Medical Center
New Haven, Connecticut

Daniel P. Petrylak, MD, has disclosed that he has received consulting fees from Ada Cap (Advanced Accelerator Applications), Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Exelixis, Incyte, Janssen, Lilly, Pfizer, Pharmacyclics, Roche, Seattle Genetics, and UroGen; has received funds for research support from Ada Cap, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Clovis, Endocyte, Genentech, Innocrin, Lilly, MedImmune, Merck, Novartis, Pfizer, Progenics, Roche, Sanofi, Seattle Genetics; and has ownership interests in Bellicum.

Jonathan Rosenberg, MD

Attending Physician, Chief
Genitourinary Oncology Service
Division of Solid Tumor Oncology
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Jonathan E. Rosenberg, MD, has disclosed that he has received consulting fees from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Janssen Merck, Pharmacyclics, Pfizer, Roche/Genentech, and Seattle Genetics; funds for research support from Astellas, AstraZeneca, Bayer, QED Therapeutics, Roche/Genentech, and Seattle Genetics; and honoraria from Chugai.